CDT Commences Human Skin Studies with QIMA Life Sciences on Novel Tapinarof Combinations in Vitiligo

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 11, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today announced that studies have commenced with QIMA Life Sciences, a world leading preclinical dermatology CRO, marking the formal kick-off of the partnership announced on September 18, 2026. QIMA will evaluate CDT’s proprietary tapinarof combinations in vitiligo using human skin from both healthy donors and patients, generating data in the most physiologically relevant setting available at the preclinical stage. Evidence of activity in human tissue gives potential partners far greater confidence in clinical translation than conventional models.

Vitiligo affects approximately 0.5%-2.0% of the global population, with the global vitiligo drug market estimated at approximately US$2.6 billion in 2025 and projected to reach US$6.6 billion by 2030. Current treatments often prove intolerable for many patients, especially pediatric patients, leaving a significant unmet need for therapies that are both effective and well tolerated. Positive results will form the core of the licensing data package for CDT’s tapinarof combinations, supported by the Company’s solid form and method-of-use patents and Sarborg-led AI analysis. CDT’s strategy is to out-license the combinations to a partner to take them through to commercialisation.